Groupama Asset Managment trimmed its position in Insmed, Inc. (NASDAQ:INSM – Free Report) by 57.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,590 shares of the biopharmaceutical company’s stock after selling 7,585 shares during the quarter. Groupama Asset Managment’s holdings in Insmed were worth $973,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also made changes to their positions in INSM. Vanguard Group Inc. lifted its stake in Insmed by 5.7% during the fourth quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock worth $3,668,127,000 after purchasing an additional 1,140,524 shares during the last quarter. Darwin Global Management Ltd. boosted its holdings in Insmed by 2.3% in the fourth quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company’s stock worth $3,644,274,000 after purchasing an additional 475,832 shares during the period. Capital International Investors increased its stake in Insmed by 1.0% during the third quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock valued at $1,087,830,000 after purchasing an additional 74,994 shares during the last quarter. State Street Corp raised its holdings in shares of Insmed by 30.6% during the fourth quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock worth $905,312,000 after purchasing an additional 1,217,390 shares during the period. Finally, Artisan Partners Limited Partnership raised its holdings in shares of Insmed by 49.0% during the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after purchasing an additional 1,623,342 shares during the period.
Insider Activity
In other news, CEO William Lewis sold 7,605 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total transaction of $777,763.35. Following the completion of the transaction, the chief executive officer directly owned 265,432 shares in the company, valued at approximately $27,145,730.64. The trade was a 2.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Sara Bonstein sold 2,404 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $245,857.08. Following the completion of the transaction, the chief financial officer directly owned 69,082 shares of the company’s stock, valued at $7,065,016.14. This trade represents a 3.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 149,783 shares of company stock worth $22,902,672 over the last ninety days. 2.10% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on INSM
Insmed Stock Down 0.1%
Insmed stock opened at $95.70 on Friday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47. Insmed, Inc. has a one year low of $90.39 and a one year high of $212.75. The company has a 50-day simple moving average of $117.97 and a 200-day simple moving average of $147.47. The firm has a market capitalization of $20.74 billion, a P/E ratio of -16.64 and a beta of 0.79.
Insmed (NASDAQ:INSM – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.14. The firm had revenue of $305.96 million for the quarter, compared to the consensus estimate of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. Insmed’s quarterly revenue was up 229.7% compared to the same quarter last year. During the same period last year, the firm posted ($1.42) EPS. As a group, equities analysts expect that Insmed, Inc. will post -2.54 earnings per share for the current year.
About Insmed
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.
The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.
Recommended Stories
- Five stocks we like better than Insmed
- 3 Retail Winners Using Cash Flow to Stay Ahead
- 3 Tech ETFs That Could Bounce Back After the AI Selloff
- 3 Penny Stocks Under $5 Backed by Real Revenue Growth
- 3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM – Free Report).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.
